

A¹ 6. (Amended) A vaccine according to Claim 1 [Claims 1-5] wherein said adjuvant is recombinantly manufactured.

A² 8. (Amended) A vaccine according to Claim 1 [Claims 1-7] wherein said vaccine comprises an immunostimulating composition adapted to elicit an enhanced cytotoxic T-cell response.

10. (Amended) A vaccine according to Claim 1 [Claims 1-9] wherein said vaccine comprises[,] liposomes, biodegradable microspheres or an emulsion of antigen and adjuvant in oil.

A³ 12. (Amended) A method for the manufacture of a vaccine according to Claim 11 wherein said antigen and adjuvant [, is/] are recombinantly manufactured and are co-joined to produce a chimeric fusion protein.

13. (Amended) A method according to Claim 11 [or 12] wherein said antigen and adjuvant are cross-linked theretogether.

A⁴ 15. (Amended) A system according to Claim 14 wherein said system is adapted so that said cell secretes said antigen and/or adjuvant, and wherein when [in the instance where] both are secreted they are secreted either singularly or as a co-joined fusion protein.

A⁵ 18. (Amended) An isolated DNA molecule encoding [either or both] said antigen [and/or said adjuvant according to Claims 1-10] of Claim 1.

Please add the following new claims:

A⁶ --26. An isolated DNA molecule encoding said adjuvant of Claim 1.

27. An isolated DNA molecule encoding the recombinant fusion protein of Claim 7.
28. A vaccine according to Claim 2 wherein said soluble antigen is a protein.
29. A vaccine according to Claim 28 wherein said protein and said adjuvant are cross-linked theretogether.
30. A method according to Claim 11 wherein said antigen and said adjuvant are cross-linked theretogether.--


REMARKS

Claims 1-8, 9-15, 18, and 26-30 are presented for consideration.

Claims 3-6, 8, 10, 12, 13, 15, and 18 have been amended and Claims 26-30 have been submitted to place the Claims of the instant Application into conformity with U.S. claim practice and to thereby expedite the examination thereof. No new matter has been entered.

Favorable consideration and an early action on the merits are believed to be in order, and are courteously solicited.

Respectfully submitted,


MICHAEL D. DAVIS
Attorney for Applicant(s)
Registration No. 39,161

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Date: October 9, 1998